Hindustan Times ST (Jaipur)

Serum Institute seeks DCGI’S nod to manufactur­e Sputnik V

- Press Trust of India

The Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission to manufactur­e the Sputnik V Covid-19 vaccine for examinatio­n, test and analysis at its licensed Hadapsar facility in Pune, official sources said on Thursday.

The Pune-based firm has collaborat­ed with the Gamaleya Research Institute of Epidemiolo­gy and Microbiolo­gy, Moscow for developing Sputnik V at its Hadapsar facility.

On May 18, the SII had also applied to the Review Committee on Genetic Manipulati­on (RCGM), Department of Biotechnol­ogy seeking clearance for the import of strains or seed lots and cell banks and for carrying out research and developmen­t, the sources said.

The RCGM has raised certain queries over the SII’S applicatio­n and sought a copy of the material transfer agreement between the Pune-based firm and the Gamaleya Research Institute of Epidemiolo­gy and Microbiolo­gy.

Russia’s Sputnik V vaccine is currently being manufactur­ed by Dr Reddy’s Laboratori­es in India.

“The Serum Institute of India (SII) put up an applicatio­n to the Drugs Controller General of India (DCGI) on Wednesday seeking permission to manufactur­e Covid-19 vaccine Sputnik V for examinatio­n, test and analysis at its licensed Hadapsar facility,” an official source said.

Once these approvals are received, Serum Institute plans to seek restricted emergency use permission for the vaccine in India.

The SII has already told the government that it will be able to manufactur­e and supply 10 crore Covishield doses in June, while it is also manufactur­ing the Novavax vaccine, the regulatory clearance for which is awaited from the United States.

The vaccine was given emergency use authorisat­ion (EUA) by the Drug Controller General of India in April.

A consignmen­t of 30 lakh doses of Sputnik V landed in Hyderabad on Tuesday.

Meanwhile, on Monday, the Serum institute of India will raise production of the Astrazenec­a Covid-19 vaccine to about 90 million doses in June from about 65 million a month now, a company spokesman said.

 ??  ??

Newspapers in English

Newspapers from India